D
Pfizer Inc.
PFE
$25.36
$0.10470.41%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
D
Sell
11/9/2023Downgrade
Pfizer Inc. (PFE) was downgraded to D+ from C- on 11/9/2023 due to a major decline in the growth index, valuation index and solvency index. EBIT declined 410.35% from $2.66B to -$8.25B, and earnings per share declined from $0.4096 to -$0.4219.
Pfizer Inc. (PFE) was downgraded to D+ from C- on 11/9/2023 due to a major decline in the growth index, valuation index and solvency index. EBIT declined 410.35% from $2.66B to -$8.25B, and earnings per share declined from $0.4096 to -$0.4219.
C
Hold
9/20/2023Downgrade
Pfizer Inc. (PFE) was downgraded to C- from C on 9/20/2023 due to a significant decline in the growth index, total return index and volatility index. Operating cash flow declined 199.67% from $1.21B to -$1.21B, EBIT declined 60.12% from $6.66B to $2.66B, and earnings per share declined from $0.9702 to $0.4096.
Pfizer Inc. (PFE) was downgraded to C- from C on 9/20/2023 due to a significant decline in the growth index, total return index and volatility index. Operating cash flow declined 199.67% from $1.21B to -$1.21B, EBIT declined 60.12% from $6.66B to $2.66B, and earnings per share declined from $0.9702 to $0.4096.
C
Hold
4/21/2023Downgrade
Pfizer Inc. (PFE) was downgraded to C from C+ on 4/21/2023 due to a noticeable decline in the volatility index and solvency index.
Pfizer Inc. (PFE) was downgraded to C from C+ on 4/21/2023 due to a noticeable decline in the volatility index and solvency index.
C
Hold
2/27/2023Downgrade
Pfizer Inc. (PFE) was downgraded to C+ from B- on 2/27/2023 due to a decline in the total return index, growth index and volatility index. EBIT declined 43.85% from $10.15B to $5.7B, and earnings per share declined from $1.5063 to $0.872.
Pfizer Inc. (PFE) was downgraded to C+ from B- on 2/27/2023 due to a decline in the total return index, growth index and volatility index. EBIT declined 43.85% from $10.15B to $5.7B, and earnings per share declined from $1.5063 to $0.872.
B
Buy
1/23/2023Downgrade
Pfizer Inc. (PFE) was downgraded to B- from B on 1/23/2023 due to a decline in the volatility index.
Pfizer Inc. (PFE) was downgraded to B- from B on 1/23/2023 due to a decline in the volatility index.
B
Buy
1/6/2023Upgraded
Pfizer Inc. (PFE) was upgraded to B from B- on 1/6/2023 due to an increase in the total return index, valuation index and dividend index.
Pfizer Inc. (PFE) was upgraded to B from B- on 1/6/2023 due to an increase in the total return index, valuation index and dividend index.
B
Buy
12/21/2022Downgrade
Pfizer Inc. (PFE) was downgraded to B- from B on 12/21/2022 due to a substantial decline in the total return index.
Pfizer Inc. (PFE) was downgraded to B- from B on 12/21/2022 due to a substantial decline in the total return index.
B
Buy
1/7/2022Upgraded
Pfizer Inc. (PFE) was upgraded to B from B- on 1/7/2022 due to an increase in the total return index and volatility index.
Pfizer Inc. (PFE) was upgraded to B from B- on 1/7/2022 due to an increase in the total return index and volatility index.
B
Buy
12/21/2021Downgrade
Pfizer Inc. (PFE) was downgraded to B- from B on 12/21/2021 due to a decline in the valuation index and dividend index.
Pfizer Inc. (PFE) was downgraded to B- from B on 12/21/2021 due to a decline in the valuation index and dividend index.
B
Buy
11/15/2021Upgraded
Pfizer Inc. (PFE) was upgraded to B from B- on 11/15/2021 due to a major increase in the valuation index, total return index and growth index. Earnings per share increased from $0.9842 to $1.4184, EBIT increased 41.92% from $6.23B to $8.84B, and total revenue increased 26.96% from $18.98B to $24.09B.
Pfizer Inc. (PFE) was upgraded to B from B- on 11/15/2021 due to a major increase in the valuation index, total return index and growth index. Earnings per share increased from $0.9842 to $1.4184, EBIT increased 41.92% from $6.23B to $8.84B, and total revenue increased 26.96% from $18.98B to $24.09B.
B
Buy
8/16/2021Upgraded
Pfizer Inc. (PFE) was upgraded to B- from C+ on 8/16/2021 due to an increase in the volatility index, total return index and solvency index.
Pfizer Inc. (PFE) was upgraded to B- from C+ on 8/16/2021 due to an increase in the volatility index, total return index and solvency index.
C
Hold
7/9/2021Upgraded
Pfizer Inc. (PFE) was upgraded to C+ from C on 7/9/2021 due to an increase in the volatility index, total return index and valuation index.
Pfizer Inc. (PFE) was upgraded to C+ from C on 7/9/2021 due to an increase in the volatility index, total return index and valuation index.
C
Hold
6/24/2021Downgrade
Pfizer Inc. (PFE) was downgraded to C from C+ on 6/24/2021 due to a decline in the valuation index.
Pfizer Inc. (PFE) was downgraded to C from C+ on 6/24/2021 due to a decline in the valuation index.
C
Hold
6/7/2021Upgraded
Pfizer Inc. (PFE) was upgraded to C+ from C on 6/7/2021 due to a large increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.1054 to $0.8616, EBIT increased 215.07% from $1.63B to $5.14B, and total revenue increased 24.8% from $11.68B to $14.58B.
Pfizer Inc. (PFE) was upgraded to C+ from C on 6/7/2021 due to a large increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.1054 to $0.8616, EBIT increased 215.07% from $1.63B to $5.14B, and total revenue increased 24.8% from $11.68B to $14.58B.
C
Hold
11/12/2020Downgrade
Pfizer Inc. (PFE) was downgraded to C from C+ on 11/12/2020 due to a significant decline in the growth index, valuation index and efficiency index. Operating cash flow declined 41.21% from $3.56B to $2.09B, earnings per share declined from $0.61 to $0.39, and net income declined 35.96% from $3.43B to $2.19B.
Pfizer Inc. (PFE) was downgraded to C from C+ on 11/12/2020 due to a significant decline in the growth index, valuation index and efficiency index. Operating cash flow declined 41.21% from $3.56B to $2.09B, earnings per share declined from $0.61 to $0.39, and net income declined 35.96% from $3.43B to $2.19B.
C
Hold
9/8/2020Upgraded
Pfizer Inc. (PFE) was upgraded to C+ from C on 9/8/2020 due to an increase in the volatility index and valuation index.
Pfizer Inc. (PFE) was upgraded to C+ from C on 9/8/2020 due to an increase in the volatility index and valuation index.
C
Hold
8/7/2020Downgrade
Pfizer Inc. (PFE) was downgraded to C from C+ on 8/7/2020 due to a noticeable decline in the valuation index, solvency index and total return index. Debt to equity increased from 0.8 to 0.99.
Pfizer Inc. (PFE) was downgraded to C from C+ on 8/7/2020 due to a noticeable decline in the valuation index, solvency index and total return index. Debt to equity increased from 0.8 to 0.99.
C
Hold
7/23/2020Upgraded
Pfizer Inc. (PFE) was upgraded to C+ from C on 7/23/2020 due to an increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.0625 to $0.61, EBIT increased 92% from $2.29B to $4.39B, and the quick ratio increased from 0.59 to 0.7.
Pfizer Inc. (PFE) was upgraded to C+ from C on 7/23/2020 due to an increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.0625 to $0.61, EBIT increased 92% from $2.29B to $4.39B, and the quick ratio increased from 0.59 to 0.7.
C
Hold
3/20/2020Downgrade
Pfizer Inc. (PFE) was downgraded to C from C+ on 3/20/2020 due to a decline in the volatility index.
Pfizer Inc. (PFE) was downgraded to C from C+ on 3/20/2020 due to a decline in the volatility index.
C
Hold
3/19/2020Downgrade
Pfizer Inc. (PFE) was downgraded to C+ from B- on 3/19/2020 due to a decline in the volatility index, total return index and solvency index.
Pfizer Inc. (PFE) was downgraded to C+ from B- on 3/19/2020 due to a decline in the volatility index, total return index and solvency index.
B
Buy
3/4/2020Upgraded
Pfizer Inc. (PFE) was upgraded to B- from C+ on 3/4/2020 due to a noticeable increase in the valuation index, volatility index and efficiency index.
Pfizer Inc. (PFE) was upgraded to B- from C+ on 3/4/2020 due to a noticeable increase in the valuation index, volatility index and efficiency index.
C
Hold
2/24/2020Downgrade
Pfizer Inc. (PFE) was downgraded to C+ from B- on 2/24/2020 due to a decline in the total return index and volatility index.
Pfizer Inc. (PFE) was downgraded to C+ from B- on 2/24/2020 due to a decline in the total return index and volatility index.
B
Buy
1/7/2020Upgraded
Pfizer Inc. (PFE) was upgraded to B- from C+ on 1/7/2020 due to an increase in the valuation index and total return index.
Pfizer Inc. (PFE) was upgraded to B- from C+ on 1/7/2020 due to an increase in the valuation index and total return index.
C
Hold
9/25/2019Downgrade
Pfizer Inc. (PFE) was downgraded to C+ from B- on 9/25/2019 due to a large decline in the total return index, volatility index and solvency index. The quick ratio declined from 0.85 to 0.83, and debt to equity increased from 0.78 to 0.79.
Pfizer Inc. (PFE) was downgraded to C+ from B- on 9/25/2019 due to a large decline in the total return index, volatility index and solvency index. The quick ratio declined from 0.85 to 0.83, and debt to equity increased from 0.78 to 0.79.
B
Buy
7/30/2019Downgrade
Pfizer Inc. (PFE) was downgraded to B- from B on 7/30/2019 due to a large decline in the volatility index, growth index and solvency index. Operating cash flow declined 64.16% from $4.74B to $1.7B, debt to equity increased from 0.66 to 0.79, and the quick ratio declined from 0.95 to 0.85.
Pfizer Inc. (PFE) was downgraded to B- from B on 7/30/2019 due to a large decline in the volatility index, growth index and solvency index. Operating cash flow declined 64.16% from $4.74B to $1.7B, debt to equity increased from 0.66 to 0.79, and the quick ratio declined from 0.95 to 0.85.
B
Buy
3/4/2019Downgrade
Pfizer Inc. (PFE) was downgraded to B from B+ on 3/4/2019 due to a significant decline in the valuation index, growth index and solvency index. Earnings per share declined from $0.6918 to -$0.0679, debt to equity increased from 0.58 to 0.66, and EBIT declined 12.18% from $3.93B to $3.45B.
Pfizer Inc. (PFE) was downgraded to B from B+ on 3/4/2019 due to a significant decline in the valuation index, growth index and solvency index. Earnings per share declined from $0.6918 to -$0.0679, debt to equity increased from 0.58 to 0.66, and EBIT declined 12.18% from $3.93B to $3.45B.
B
Buy
2/21/2019Downgrade
Pfizer Inc. (PFE) was downgraded to B+ from A- on 2/21/2019 due to a decline in the total return index and volatility index.
Pfizer Inc. (PFE) was downgraded to B+ from A- on 2/21/2019 due to a decline in the total return index and volatility index.
A
Buy
1/11/2019Upgraded
Pfizer Inc. (PFE) was upgraded to A- from B+ on 1/11/2019 due to an increase in the total return index.
Pfizer Inc. (PFE) was upgraded to A- from B+ on 1/11/2019 due to an increase in the total return index.
B
Buy
12/27/2018Downgrade
Pfizer Inc. (PFE) was downgraded to B+ from A- on 12/27/2018 due to a decline in the total return index, growth index and dividend index. EBIT declined 5.28% from $4.32B to $4.09B, and total revenue declined 1.25% from $13.47B to $13.3B.
Pfizer Inc. (PFE) was downgraded to B+ from A- on 12/27/2018 due to a decline in the total return index, growth index and dividend index. EBIT declined 5.28% from $4.32B to $4.09B, and total revenue declined 1.25% from $13.47B to $13.3B.
A
Buy
9/10/2018Upgraded
Pfizer Inc. (PFE) was upgraded to A- from B on 9/10/2018 due to a large increase in the growth index, volatility index and total return index. Operating cash flow increased 94% from $1.98B to $3.85B, earnings per share increased from $0.5898 to $0.65, and total revenue increased 4.34% from $12.91B to $13.47B.
Pfizer Inc. (PFE) was upgraded to A- from B on 9/10/2018 due to a large increase in the growth index, volatility index and total return index. Operating cash flow increased 94% from $1.98B to $3.85B, earnings per share increased from $0.5898 to $0.65, and total revenue increased 4.34% from $12.91B to $13.47B.
B
Buy
5/21/2018Upgraded
Pfizer Inc. (PFE) was upgraded to B from B- on 5/21/2018 due to an increase in the volatility index, valuation index and efficiency index.
Pfizer Inc. (PFE) was upgraded to B from B- on 5/21/2018 due to an increase in the volatility index, valuation index and efficiency index.
B
Buy
5/8/2018Downgrade
Pfizer Inc. (PFE) was downgraded to B- from B on 5/8/2018 due to a decline in the volatility index and total return index.
Pfizer Inc. (PFE) was downgraded to B- from B on 5/8/2018 due to a decline in the volatility index and total return index.
B
Buy
4/12/2018Upgraded
Pfizer Inc. (PFE) was upgraded to B from B- on 4/12/2018 due to an increase in the volatility index and valuation index.
Pfizer Inc. (PFE) was upgraded to B from B- on 4/12/2018 due to an increase in the volatility index and valuation index.
B
Buy
3/28/2018Downgrade
Pfizer Inc. (PFE) was downgraded to B- from B on 3/28/2018 due to a noticeable decline in the volatility index, efficiency index and dividend index.
Pfizer Inc. (PFE) was downgraded to B- from B on 3/28/2018 due to a noticeable decline in the volatility index, efficiency index and dividend index.
B
Buy
2/20/2018Upgraded
Pfizer Inc. (PFE) was upgraded to B from B- on 2/20/2018 due to an increase in the volatility index, valuation index and dividend index.
Pfizer Inc. (PFE) was upgraded to B from B- on 2/20/2018 due to an increase in the volatility index, valuation index and dividend index.
B
Buy
2/5/2018Downgrade
Pfizer Inc. (PFE) was downgraded to B- from B on 2/5/2018 due to a noticeable decline in the volatility index and dividend index.
Pfizer Inc. (PFE) was downgraded to B- from B on 2/5/2018 due to a noticeable decline in the volatility index and dividend index.
B
Buy
10/10/2017Upgraded
Pfizer Inc. (PFE) was upgraded to B from B- on 10/10/2017 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 104.66% from $1.59B to $3.25B, total revenue increased 0.92% from $12.78B to $12.9B, and earnings per share increased from $0.51 to $0.5103.
Pfizer Inc. (PFE) was upgraded to B from B- on 10/10/2017 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 104.66% from $1.59B to $3.25B, total revenue increased 0.92% from $12.78B to $12.9B, and earnings per share increased from $0.51 to $0.5103.
B
Buy
6/5/2017Upgraded
Pfizer Inc. (PFE) was upgraded to B- from C+ on 6/5/2017 due to a noticeable increase in the growth index, volatility index and valuation index. Earnings per share increased from $0.1228 to $0.51, and EBIT increased 62.76% from $2.55B to $4.16B.
Pfizer Inc. (PFE) was upgraded to B- from C+ on 6/5/2017 due to a noticeable increase in the growth index, volatility index and valuation index. Earnings per share increased from $0.1228 to $0.51, and EBIT increased 62.76% from $2.55B to $4.16B.
C
Hold
4/24/2017Upgraded
Pfizer Inc. (PFE) was upgraded to C+ from C on 4/24/2017 due to an increase in the valuation index, growth index and efficiency index. Total revenue increased 4.46% from $13.05B to $13.63B.
Pfizer Inc. (PFE) was upgraded to C+ from C on 4/24/2017 due to an increase in the valuation index, growth index and efficiency index. Total revenue increased 4.46% from $13.05B to $13.63B.
C
Hold
11/17/2016Downgrade
Pfizer Inc. (PFE) was downgraded to C from C+ on 11/17/2016 due to a decline in the volatility index and valuation index.
Pfizer Inc. (PFE) was downgraded to C from C+ on 11/17/2016 due to a decline in the volatility index and valuation index.
C
Hold
11/14/2016Downgrade
Pfizer Inc. (PFE) was downgraded to C+ from B- on 11/14/2016 due to a decline in the valuation index, volatility index and efficiency index. Net income declined 34.62% from $2.02B to $1.32B.
Pfizer Inc. (PFE) was downgraded to C+ from B- on 11/14/2016 due to a decline in the valuation index, volatility index and efficiency index. Net income declined 34.62% from $2.02B to $1.32B.
B
Buy
11/9/2016Upgraded
Pfizer Inc. (PFE) was upgraded to B- from C on 11/9/2016 due to a noticeable increase in the volatility index and valuation index.
Pfizer Inc. (PFE) was upgraded to B- from C on 11/9/2016 due to a noticeable increase in the volatility index and valuation index.
C
Hold
11/8/2016Downgrade
Pfizer Inc. (PFE) was downgraded to C from B- on 11/8/2016 due to a noticeable decline in the volatility index and total return index.
Pfizer Inc. (PFE) was downgraded to C from B- on 11/8/2016 due to a noticeable decline in the volatility index and total return index.
B
Buy
11/1/2016Upgraded
Pfizer Inc. (PFE) was upgraded to B- from C+ on 11/1/2016 due to an increase in the valuation index and dividend index.
Pfizer Inc. (PFE) was upgraded to B- from C+ on 11/1/2016 due to an increase in the valuation index and dividend index.
C
Hold
9/14/2016Downgrade
Pfizer Inc. (PFE) was downgraded to C+ from B- on 9/14/2016 due to a noticeable decline in the total return index.
Pfizer Inc. (PFE) was downgraded to C+ from B- on 9/14/2016 due to a noticeable decline in the total return index.
B
Buy
8/12/2016Downgrade
Pfizer Inc. (PFE) was downgraded to B- from B on 8/12/2016 due to a noticeable decline in the growth index, valuation index and efficiency index. Net income declined 33.06% from $3.02B to $2.02B, earnings per share declined from $0.49 to $0.3302, and EBIT declined 6.37% from $4.14B to $3.88B.
Pfizer Inc. (PFE) was downgraded to B- from B on 8/12/2016 due to a noticeable decline in the growth index, valuation index and efficiency index. Net income declined 33.06% from $3.02B to $2.02B, earnings per share declined from $0.49 to $0.3302, and EBIT declined 6.37% from $4.14B to $3.88B.
B
Buy
8/10/2016Upgraded
Pfizer Inc. (PFE) was upgraded to B from B- on 8/10/2016 due to a major increase in the total return index and volatility index.
Pfizer Inc. (PFE) was upgraded to B from B- on 8/10/2016 due to a major increase in the total return index and volatility index.
B
Buy
6/8/2016Upgraded
Pfizer Inc. (PFE) was upgraded to B- from C+ on 6/8/2016 due to a noticeable increase in the volatility index, solvency index and total return index.
Pfizer Inc. (PFE) was upgraded to B- from C+ on 6/8/2016 due to a noticeable increase in the volatility index, solvency index and total return index.
C
Hold
5/18/2016Upgraded
Pfizer Inc. (PFE) was upgraded to C+ from C on 5/18/2016 due to a large increase in the growth index, total return index and valuation index. Earnings per share increased from -$0.0305 to $0.49, and EBIT increased 83.28% from $2.26B to $4.14B.
Pfizer Inc. (PFE) was upgraded to C+ from C on 5/18/2016 due to a large increase in the growth index, total return index and valuation index. Earnings per share increased from -$0.0305 to $0.49, and EBIT increased 83.28% from $2.26B to $4.14B.
C
Hold
3/4/2016Downgrade
Pfizer Inc. (PFE) was downgraded to C from C+ on 3/4/2016 due to a large decline in the growth index, total return index and valuation index. Earnings per share declined from $0.3413 to -$0.0305, and EBIT declined 42.86% from $3.96B to $2.26B.
Pfizer Inc. (PFE) was downgraded to C from C+ on 3/4/2016 due to a large decline in the growth index, total return index and valuation index. Earnings per share declined from $0.3413 to -$0.0305, and EBIT declined 42.86% from $3.96B to $2.26B.
C
Hold
2/3/2016Downgrade
Pfizer Inc. (PFE) was downgraded to C+ from B- on 2/3/2016 due to a decline in the volatility index, total return index and solvency index.
Pfizer Inc. (PFE) was downgraded to C+ from B- on 2/3/2016 due to a decline in the volatility index, total return index and solvency index.
B
Buy
11/6/2015Downgrade
Pfizer Inc. (PFE) was downgraded to B- from B on 11/6/2015 due to a substantial decline in the volatility index, total return index and valuation index.
Pfizer Inc. (PFE) was downgraded to B- from B on 11/6/2015 due to a substantial decline in the volatility index, total return index and valuation index.
B
Buy
7/15/2015Downgrade
Pfizer Inc. (PFE) was downgraded to B from B+ on 7/15/2015 due to a noticeable decline in the volatility index and total return index.
Pfizer Inc. (PFE) was downgraded to B from B+ on 7/15/2015 due to a noticeable decline in the volatility index and total return index.
B
Buy
5/8/2015Upgraded
Pfizer Inc. (PFE) was upgraded to B+ from B on 5/8/2015 due to an increase in the growth index, volatility index and valuation index. Earnings per share increased from $0.1925 to $0.3808.
Pfizer Inc. (PFE) was upgraded to B+ from B on 5/8/2015 due to an increase in the growth index, volatility index and valuation index. Earnings per share increased from $0.1925 to $0.3808.
B
Buy
2/27/2015Downgrade
Pfizer Inc. (PFE) was downgraded to B from B+ on 2/27/2015 due to a decline in the valuation index, solvency index and dividend index. Debt to equity increased from 0.48 to 0.51.
Pfizer Inc. (PFE) was downgraded to B from B+ on 2/27/2015 due to a decline in the valuation index, solvency index and dividend index. Debt to equity increased from 0.48 to 0.51.
B
Buy
2/10/2015Upgraded
Pfizer Inc. (PFE) was upgraded to B+ from B on 2/10/2015 due to a large increase in the volatility index and total return index.
Pfizer Inc. (PFE) was upgraded to B+ from B on 2/10/2015 due to a large increase in the volatility index and total return index.
B
Buy
1/7/2015Upgraded
Pfizer Inc. (PFE) was upgraded to B from B- on 1/7/2015 due to an increase in the volatility index, total return index and valuation index.
Pfizer Inc. (PFE) was upgraded to B from B- on 1/7/2015 due to an increase in the volatility index, total return index and valuation index.
B
Buy
12/23/2014Downgrade
Pfizer Inc. (PFE) was downgraded to B- from B on 12/23/2014 due to a decline in the volatility index, total return index and valuation index.
Pfizer Inc. (PFE) was downgraded to B- from B on 12/23/2014 due to a decline in the volatility index, total return index and valuation index.
B
Buy
12/8/2014Upgraded
Pfizer Inc. (PFE) was upgraded to B from B- on 12/8/2014 due to an increase in the volatility index.
Pfizer Inc. (PFE) was upgraded to B from B- on 12/8/2014 due to an increase in the volatility index.
B
Buy
11/7/2014Downgrade
Pfizer Inc. (PFE) was downgraded to B- from B on 11/7/2014 due to a substantial decline in the valuation index, growth index and volatility index. Earnings per share declined from $0.4519 to $0.4195, EBIT declined 4.85% from $4.27B to $4.06B, and total revenue declined 3.23% from $12.77B to $12.36B.
Pfizer Inc. (PFE) was downgraded to B- from B on 11/7/2014 due to a substantial decline in the valuation index, growth index and volatility index. Earnings per share declined from $0.4519 to $0.4195, EBIT declined 4.85% from $4.27B to $4.06B, and total revenue declined 3.23% from $12.77B to $12.36B.
B
Buy
8/6/2014Downgrade
Pfizer Inc. (PFE) was downgraded to B from A- on 8/6/2014 due to a large decline in the volatility index and total return index.
Pfizer Inc. (PFE) was downgraded to B from A- on 8/6/2014 due to a large decline in the volatility index and total return index.
A
Buy
6/23/2014Downgrade
Pfizer Inc. (PFE) was downgraded to A- from A on 6/23/2014 due to a large decline in the volatility index, growth index and total return index. Operating cash flow declined 49.27% from $5.79B to $2.94B, total revenue declined 16.26% from $13.56B to $11.35B, and earnings per share declined from $0.3931 to $0.3613.
Pfizer Inc. (PFE) was downgraded to A- from A on 6/23/2014 due to a large decline in the volatility index, growth index and total return index. Operating cash flow declined 49.27% from $5.79B to $2.94B, total revenue declined 16.26% from $13.56B to $11.35B, and earnings per share declined from $0.3931 to $0.3613.
A
Buy
3/28/2014Upgraded
Pfizer Inc. (PFE) was upgraded to A from A- on 3/28/2014 due to a major increase in the valuation index, total return index and volatility index.
Pfizer Inc. (PFE) was upgraded to A from A- on 3/28/2014 due to a major increase in the valuation index, total return index and volatility index.
NYSE
04/26/2024 11:02AM Eastern
Quotes delayed
